Fmr LLC Has $386.17 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Fmr LLC lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 41.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,077,628 shares of the biotechnology company’s stock after purchasing an additional 314,004 shares during the quarter. Fmr LLC owned about 2.41% of United Therapeutics worth $386,168,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in UTHR. B. Riley Wealth Advisors Inc. bought a new position in shares of United Therapeutics in the 1st quarter worth $219,000. Cetera Advisors LLC bought a new position in shares of United Therapeutics in the first quarter valued at $475,000. GAMMA Investing LLC lifted its stake in shares of United Therapeutics by 84.8% in the second quarter. GAMMA Investing LLC now owns 390 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 179 shares in the last quarter. DNB Asset Management AS increased its position in shares of United Therapeutics by 18.3% during the second quarter. DNB Asset Management AS now owns 7,800 shares of the biotechnology company’s stock worth $2,485,000 after acquiring an additional 1,208 shares in the last quarter. Finally, Bank & Trust Co acquired a new stake in shares of United Therapeutics in the 2nd quarter worth about $420,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Nilda Mesa sold 224 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares in the company, valued at approximately $2,384,215.24. The trade was a 3.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 127,227 shares of company stock valued at $47,398,820 in the last 90 days. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 2.0 %

Shares of NASDAQ UTHR opened at $370.49 on Friday. The firm’s 50-day moving average price is $367.77 and its 200-day moving average price is $335.19. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The company has a market cap of $16.54 billion, a PE ratio of 16.27, a PEG ratio of 1.10 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.38 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of analyst reports. Wells Fargo & Company lifted their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group increased their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, The Goldman Sachs Group boosted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.